1 1

Jakavi 15 mg (Ruxolitinib)

Jakavi 15 mg (Ruxolitinib)

Brand Name: Jakavi
Origin: Switzerland / manufacturing origin may vary by market.
Small Orders: Available/YES
Tags: 15mg Tablet , Blood Disorder Treatment , Cancer Medicine , Graft Versus Host Disease , GVHD Treatment , JAK inhibitor , JAK1 Inhibitor , JAK2 Inhibitor , Jakavi 15mg , Jakavi Tablet , Myelofibrosis Treatment , Novartis , Oncology Medicine , Polycythemia Vera Treatment , Prescription Medicine , Ruxolitinib , Ruxolitinib 15mg , Targeted Therapy
Ver todos los detalles
  • Details
  • Description
Packaging Size: 14 or 56 tablets; 168 tablets may also be available as a multipack.
Strength: 15 mg
Composition: Ruxolitinib 15 mg (as ruxolitinib phosphate) per tablet.
Treatment: Myelofibrosis, polycythemia vera, and acute/chronic graft-versus-host disease (GVHD), according to the applicable indication.
Form: Tablet
Brand: Jakavi
Quantity Unit: 1 tablet
Manufacturer: Novartis; manufacturing sites vary by market.

Jakavi 15 mg (Ruxolitinib) is a prescription medicine used to treat myelofibrosis, polycythemia vera, and certain cases of graft-versus-host disease (GVHD). It works by inhibiting JAK1 and JAK2 enzymes, helping control abnormal blood-cell production, reduce spleen enlargement, and relieve disease-related symptoms. It is used under medical supervision with regular blood-count monitoring.

Everyone Deserves Access to Life-saving Treatment Of Cancer. We are a Trusted Cancer Medicine seller delivering certified medications to every corner of the world.